RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to beat back tough leukemia
Disease control Recruiting nowThis study tests whether a new combination of drugs (venetoclax plus CACAG) works better than a standard mix (BAT) for people whose acute myeloid leukemia has come back or hasn't responded to treatment. About 200 adults aged 14 to 75 will take part. The main goal is to see how ma…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
New hope for tough leukemia: experimental drug BL-M11D1 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called BL-M11D1 in 120 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the disease. Participants must …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for tough leukemia: experimental drug targets resistant cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called NMS-03597812 in adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The study includes people with a specific genetic change (TP53 mutation) that often makes the cancer harde…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Engineered immune cells take aim at two hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that target a protein called CD70 found on cancer cells. The study enrolls 25 adults with T-cell lymphoma or acute myeloid leukemia that has come back or not responded to standard …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 18, 2026 12:07 UTC